{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T03:06:26Z","timestamp":1794279986122,"version":"4.9.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014387","name":"Acadia Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014387","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020841","name":"Envision","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020841","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.clinthera.2026.06.019","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T11:24:12Z","timestamp":1784719452000},"page":"1089-1098","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader\u2013Willi Syndrome: Results From the Randomized, Placebo-Controlled, Phase 3 COMPASS PWS Study"],"prefix":"10.1016","volume":"48","author":[{"given":"Elizabeth","family":"Roof","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa V.","family":"Strong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane E.J.","family":"Stafford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepan","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sani M.","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0970-2158","authenticated-orcid":false,"given":"Dilesh","family":"Doshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alana","family":"Salvucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"Youakim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn E.","family":"McCandless","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2026.06.019_bib0001","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13023-017-0673-6","article-title":"Early diagnosis and care is achieved but should be improved in infants with Prader-Willi syndrome","volume":"12","author":"Bar","year":"2017","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.clinthera.2026.06.019_bib0002","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/gim.0b013e31822bead0","article-title":"Prader-Willi syndrome","volume":"14","author":"Cassidy","year":"2012","journal-title":"Genet Med"},{"key":"10.1016\/j.clinthera.2026.06.019_bib0003","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1136\/adc.88.3.263","article-title":"Birth prevalence of Prader-Willi syndrome in Australia","volume":"88","author":"Smith","year":"2003","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.clinthera.2026.06.019_bib0004","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1136\/jmg.38.11.792","article-title":"Population prevalence and estimated birth incidence and mortality rate for people with Prader-Willi syndrome in one UK Health Region","volume":"38","author":"Whittington","year":"2001","journal-title":"J Med Genet"},{"key":"10.1016\/j.clinthera.2026.06.019_bib0005","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/ajmg.1320350306","article-title":"Prader-Willi syndrome: current understanding of cause and diagnosis","volume":"35","author":"Butler","year":"1990","journal-title":"Am J Med Genet"},{"key":"10.1016\/j.clinthera.2026.06.019_bib0006","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1007\/s40618-015-0312-9","article-title":"Prader-Willi syndrome: a review of clinical, genetic, and endocrine findings","volume":"38","author":"Angulo","year":"2015","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.clinthera.2026.06.019_bib0007","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2174\/1573396315666190716120925","article-title":"Prader-Willi syndrome\u2014clinical genetics, diagnosis and treatment approaches: an update","volume":"15","author":"Butler","year":"2019","journal-title":"Curr Pediatr Rev"},{"key":"10.1016\/j.clinthera.2026.06.019_bib0008","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S1462399405009531","article-title":"Prader-Willi syndrome: clinical genetics, cytogenetics and molecular biology","volume":"7","author":"Bittel","year":"2005","journal-title":"Expert Rev Mol Med"},{"key":"10.1016\/j.clinthera.2026.06.019_bib0009","doi-asserted-by":"crossref","DOI":"10.1111\/jne.12994","article-title":"Hypothalamic neuropeptides and neurocircuitries in Prader Willi syndrome","volume":"33","author":"Correa-da-Silva","year":"2021","journal-title":"J Neuroendocrinol"},{"key":"10.1016\/j.clinthera.2026.06.019_bib0010","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1002\/ajmg.a.33951","article-title":"Nutritional phases in Prader-Willi syndrome","volume":"155A","author":"Miller","year":"2011","journal-title":"Am J Med Genet A"},{"key":"10.1016\/j.clinthera.2026.06.019_bib0011","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s11689-021-09373-2","article-title":"Behavioral features in Prader-Willi syndrome (PWS): consensus paper from the International PWS Clinical Trial Consortium","volume":"13","author":"Schwartz","year":"2021","journal-title":"J Neurodev Disord"},{"key":"10.1016\/j.clinthera.2026.06.019_bib0012","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1080\/13696998.2018.1528980","article-title":"Caregiver priorities for endpoints to evaluate treatments for Prader-Willi syndrome: a best-worst scaling","volume":"21","author":"Tsai","year":"2018","journal-title":"J Med Econ"},{"key":"10.1016\/j.clinthera.2026.06.019_bib0013","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1124\/pr.120.019398","article-title":"Is oxytocin \"nature\u2019s medicine\"?","volume":"72","author":"Carter","year":"2020","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.clinthera.2026.06.019_bib0014","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1152\/physrev.00031.2017","article-title":"The oxytocin receptor: from intracellular signaling to behavior","volume":"98","author":"Jurek","year":"2018","journal-title":"Physiol Rev"},{"key":"10.1016\/j.clinthera.2026.06.019_bib0015","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1172\/JCI88648","article-title":"Deficiency in prohormone convertase PC1 impairs prohormone processing in Prader-Willi syndrome","volume":"127","author":"Burnett","year":"2017","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clinthera.2026.06.019_bib0016","first-page":"573","article-title":"Alterations in the hypothalamic paraventricular nucleus and its oxytocin neurons (putative satiety cells) in Prader-Willi syndrome: a study of five cases","volume":"80","author":"Swaab","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2026.06.019_bib0017","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1016\/j.celrep.2018.03.018","article-title":"A transcriptomic signature of the hypothalamic response to fasting and BDNF deficiency in Prader-Willi syndrome","volume":"22","author":"Bochukova","year":"2018","journal-title":"Cell Rep"},{"key":"10.1016\/j.clinthera.2026.06.019_bib0018","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/ajmg.a.31606","article-title":"Whole genome microarray analysis of gene expression in Prader-Willi syndrome","volume":"143A","author":"Bittel","year":"2007","journal-title":"Am J Med Genet A"},{"key":"10.1016\/j.clinthera.2026.06.019_bib0019","doi-asserted-by":"crossref","DOI":"10.1111\/jne.13217","article-title":"Analysis of the hypothalamic oxytocin system and oxytocin receptor-expressing astrocytes in a mouse model of Prader-Willi syndrome","volume":"34","author":"Althammer","year":"2022","journal-title":"J Neuroendocrinol"},{"key":"10.1016\/j.clinthera.2026.06.019_bib0020","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.nbd.2018.09.017","article-title":"Inactivation of Magel2 suppresses oxytocin neurons through synaptic excitation-inhibition imbalance","volume":"121","author":"Ates","year":"2019","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.clinthera.2026.06.019_bib0021","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1210\/me.2008-0067","article-title":"Oxytocin deficiency mediates hyperphagic obesity of Sim1 haploinsufficient mice","volume":"22","author":"Kublaoui","year":"2008","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.clinthera.2026.06.019_bib0022","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1523\/JNEUROSCI.5444-09.2010","article-title":"Postnatal Sim1 deficiency causes hyperphagic obesity and reduced Mc4r and oxytocin expression","volume":"30","author":"Tolson","year":"2010","journal-title":"J Neurosci"},{"key":"10.1016\/j.clinthera.2026.06.019_bib0023","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.138576","article-title":"Loss of MAGEL2 in Prader-Willi syndrome leads to decreased secretory granule and neuropeptide production","volume":"5","author":"Chen","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.clinthera.2026.06.019_bib0024","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.biopsych.2014.11.010","article-title":"An early postnatal oxytocin treatment prevents social and learning deficits in adult mice deficient for Magel2, a gene involved in Prader-Willi syndrome and autism","volume":"78","author":"Meziane","year":"2015","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.clinthera.2026.06.019_bib0025","doi-asserted-by":"crossref","first-page":"4895","DOI":"10.1093\/hmg\/ddq424","article-title":"A single postnatal injection of oxytocin rescues the lethal feeding behaviour in mouse newborns deficient for the imprinted Magel2 gene","volume":"19","author":"Schaller","year":"2010","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.clinthera.2026.06.019_bib0026","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1002\/ajmg.a.38160","article-title":"Oxytocin treatment in children with Prader-Willi syndrome: a double-blind, placebo-controlled, crossover study","volume":"173","author":"Miller","year":"2017","journal-title":"Am J Med Genet A"},{"key":"10.1016\/j.clinthera.2026.06.019_bib0027","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1002\/ajmg.a.36653","article-title":"A double-blind randomized controlled trial of oxytocin nasal spray in Prader Willi syndrome","volume":"164A","author":"Einfeld","year":"2014","journal-title":"Am J Med Genet A"},{"key":"10.1016\/j.clinthera.2026.06.019_bib0028","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1111\/cen.13169","article-title":"Promising effects of oxytocin on social and food-related behaviour in young children with Prader-Willi syndrome: a randomized, double-blind, controlled crossover trial","volume":"85","author":"Kuppens","year":"2016","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.clinthera.2026.06.019_bib0029","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1750-1172-6-47","article-title":"Oxytocin may be useful to increase trust in others and decrease disruptive behaviours in patients with Prader-Willi syndrome: a randomised placebo-controlled trial in 24 patients","volume":"6","author":"Tauber","year":"2011","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.clinthera.2026.06.019_bib0030","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2016-2976","article-title":"The use of oxytocin to improve feeding and social skills in infants with Prader-Willi syndrome","volume":"139","author":"Tauber","year":"2017","journal-title":"Pediatrics"},{"key":"10.1016\/j.clinthera.2026.06.019_bib0031","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/cen.14387","article-title":"Oxytocin in young children with Prader-Willi syndrome: results of a randomized, double-blind, placebo-controlled, crossover trial investigating 3 months of oxytocin","volume":"94","author":"Damen","year":"2021","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.clinthera.2026.06.019_bib0032","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.jpsychires.2020.11.006","article-title":"Intranasal oxytocin versus placebo for hyperphagia and repetitive behaviors in children with Prader-Willi Syndrome: a randomized controlled pilot trial","volume":"137","author":"Hollander","year":"2021","journal-title":"J Psychiatr Res"},{"key":"10.1016\/j.clinthera.2026.06.019_bib0033","first-page":"180","article-title":"Oxytocin determination by radioimmunoassay","volume":"16","author":"Vankrieken","year":"1983","journal-title":"Gynecol Obstet Invest"},{"key":"10.1016\/j.clinthera.2026.06.019_bib0034","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1113\/jphysiol.1969.sp008937","article-title":"The clearance and antidiuretic potency of neurohypophysial hormones in man, and their plasma binding and stability","volume":"204","author":"Fabian","year":"1969","journal-title":"J Physiol"},{"key":"10.1016\/j.clinthera.2026.06.019_bib0035","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.yfrne.2017.10.004","article-title":"Cross-talk among oxytocin and arginine-vasopressin receptors: relevance for basic and clinical studies of the brain and periphery","volume":"51","author":"Song","year":"2018","journal-title":"Front Neuroendocrinol"},{"key":"10.1016\/j.clinthera.2026.06.019_bib0036","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.tins.2012.08.004","article-title":"Balance of brain oxytocin and vasopressin: implications for anxiety, depression, and social behaviors","volume":"35","author":"Neumann","year":"2012","journal-title":"Trends Neurosci"},{"key":"10.1016\/j.clinthera.2026.06.019_bib0037","doi-asserted-by":"crossref","DOI":"10.1210\/endocr\/bqac111","article-title":"Oxytocin, vasopressin, and social behavior: from neural circuits to clinical opportunities","volume":"163","author":"Rigney","year":"2022","journal-title":"Endocrinology"},{"key":"10.1016\/j.clinthera.2026.06.019_bib0038","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0014-2999(98)00513-5","article-title":"Oxytocin receptor binding and uterotonic activity of carbetocin and its metabolites following enzymatic degradation","volume":"355","author":"Engstr\u00f8m","year":"1998","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.clinthera.2026.06.019_bib0039","doi-asserted-by":"crossref","DOI":"10.1111\/jne.12363","article-title":"Carbetocin is a functional selective Gq agonist that does not promote oxytocin receptor recycling after inducing beta-arrestin-independent internalisation","volume":"28","author":"Passoni","year":"2016","journal-title":"J Neuroendocrinol"},{"key":"10.1016\/j.clinthera.2026.06.019_bib0040","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.98333","article-title":"Intranasal carbetocin reduces hyperphagia in individuals with Prader-Willi syndrome","volume":"3","author":"Dykens","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.clinthera.2026.06.019_bib0041","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1210\/clinem\/dgad015","article-title":"Intranasal carbetocin reduces hyperphagia, anxiousness, and distress in Prader-Willi syndrome: CARE-PWS Phase 3 Trial","volume":"108","author":"Roof","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2026.06.019_bib0042","doi-asserted-by":"crossref","first-page":"A25","DOI":"10.1016\/j.jval.2015.03.154","article-title":"Development of the Hyperphagia Questionnaire for use in Prader-Willi syndrome clinical trials","volume":"18","author":"Fehnel","year":"2015","journal-title":"Value Health"},{"key":"10.1016\/j.clinthera.2026.06.019_bib0043","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1097\/00004583-199706000-00023","article-title":"Children\u2019s Yale-Brown Obsessive Compulsive Scale: reliability and validity","volume":"36","author":"Scahill","year":"1997","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.clinthera.2026.06.019_bib0044","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jval.2022.08.004","article-title":"The Prader-Willi Syndrome Anxiousness and Distress Behaviors Questionnaire: development and psychometric validation","volume":"26","author":"Cotter","year":"2023","journal-title":"Value Health"},{"key":"10.1016\/j.clinthera.2026.06.019_bib0045","first-page":"28","article-title":"The clinical global impressions scale: applying a research tool in clinical practice","volume":"4","author":"Busner","year":"2007","journal-title":"Psychiatry (Edgmont)"},{"key":"10.1016\/j.clinthera.2026.06.019_bib0046","doi-asserted-by":"crossref","first-page":"A1339","DOI":"10.1212\/WNL.94.15_supplement.1339","article-title":"The adaptation and utility of the Clinical Global Impression scale for studying treatment outcomes in neurodevelopmental conditions","volume":"94","author":"Jaeger","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2026.06.019_bib0047","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s12955-021-01813-w","article-title":"Development of a Clinical Global Impression of Change (CGI-C) and a Caregiver Global Impression of Change (CaGI-C) measure for ambulant individuals with Duchenne muscular dystrophy","volume":"19","author":"Staunton","year":"2021","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.clinthera.2026.06.019_bib0048","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1111\/dom.13021","article-title":"Effects of MetAP2 inhibition on hyperphagia and body weight in Prader-Willi syndrome: a randomized, double-blind, placebo-controlled trial","volume":"19","author":"McCandless","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2026.06.019_bib0049","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.jclinepi.2013.08.015","article-title":"Systematic review of the Hawthorne effect: new concepts are needed to study research participation effects","volume":"67","author":"McCambridge","year":"2014","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.clinthera.2026.06.019_bib0050","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1210\/clinem\/dgad014","article-title":"Diazoxide choline extended-release tablet in people with Prader-Willi syndrome: a double-blind, placebo-controlled trial","volume":"108","author":"Miller","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2026.06.019_bib0051","doi-asserted-by":"crossref","first-page":"E532","DOI":"10.1152\/ajpendo.90590.2008","article-title":"Intracellular trafficking of the human oxytocin receptor: evidence of receptor recycling via a Rab4\/Rab5 \"short cycle\"","volume":"296","author":"Conti","year":"2009","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2026.06.019_bib0052","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1152\/physrev.2001.81.2.629","article-title":"The oxytocin receptor system: structure, function, and regulation","volume":"81","author":"Gimpl","year":"2001","journal-title":"Physiol Rev"},{"key":"10.1016\/j.clinthera.2026.06.019_bib0053","first-page":"301","article-title":"Social effects of oxytocin in humans: context and person matter","volume":"15","author":"Bartz","year":"2011","journal-title":"Trends Cogn Sci"},{"key":"10.1016\/j.clinthera.2026.06.019_bib0054","doi-asserted-by":"crossref","DOI":"10.1111\/jne.12381","article-title":"Oxytocin acting in the nucleus accumbens core decreases food intake","volume":"28","author":"Herisson","year":"2016","journal-title":"J Neuroendocrinol"},{"key":"10.1016\/j.clinthera.2026.06.019_bib0055","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1159\/000489263","article-title":"The anorexigenic neural pathways of oxytocin and their clinical implication","volume":"107","author":"Maejima","year":"2018","journal-title":"Neuroendocrinology"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291826002341?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291826002341?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T02:34:01Z","timestamp":1793846041000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291826002341"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":55,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S0149291826002341"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2026.06.019","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader\u2013Willi Syndrome: Results From the Randomized, Placebo-Controlled, Phase 3 COMPASS PWS Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2026.06.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}